Description:
ModelHuntington"sDiseaseinaDish
Wehaveappliedourinnovativetechnologytodevelophumanneuralstemcellsdirectlydifferentiatedfrom Huntington’sDiseaseiPScells. OurcellsallowHuntington"sDiseaseresearcherstobuildtheirownhumancellularmodelsinadisease-relevantgeneticandtissuecontext.
Ourready-to-usekitsallowyoutoconcentrateonyourexperimentsratherthanspendingvaluabletimeandresourcesgeneratingHuntington"sDiseaseneuralProgenitorsin-house. Aspartofthe HDNSCkit,youwillreceive Plating-XFMedium inadditiontoyourvialofhumanneuralstemcellstomaximizecellviABIlity.
HDNSCs arereadymadeandeasytodifferentiate. Theyarecapableofdifferentiatingintoaspectrumofcorticalexcitatoryandinhibitoryneuronsandremainviableincultureformonths,facilitatingreproducIBLeandlong-termstudies.
WhetheryouwanttostudyHuntington"sDiseasepathogenesisatthecellularlevel,performneurotoxicitytestingorpre-clinicaldrugscreening,webelievethat HDNSCs,alongsideouroptimized culturereagents,providetheperfectculturesystemforyourresearchsuccess.
PhaseContrastImageofHuntington"sDiseaseHumanNeuralStemCells.
TheimagewastakenatDay7invitro.InthecentreoftheimageyoucanseeHDNSCsinaneuralrosetteformation.Neuriteoutgrowthcanalsobeobserved.
Huntington"sDiseaseNeuralStemCellsExpressNeuralStem/ProgenitorCellMarkers.
HDNSCswerefixedafter7daysincultureandstainedusingourimmunocytochemistyprotocol.TheneuralstemcellswerecounterstainedwithDAPItovisualisethenuclei.Thecellscanbeseentoexpressneuralstem/progenitorcellmarkersKi67,NestinandPax6.
DAPINestinKi67
AdvantagesofAxolHDNSCs
HumancellsderivedfromdiagnosedHuntington"sDiseasepatients
Availableinindustrialquantity
Highpurityneuralstemcellpopulation
Ready-madeandeasytodifferentiate
Robustenoughtoundergogeneticmanipulation
Capableofdifferentiatingtoaspectrumofcorticalexcitatoryandinhibitoryneurons
Remainviableincultureformonthstofacilitatereproducibleandlongtermstudies
Applications
StudyingHuntington"sDiseasepathogenesisatthecellularlevel
StudyingneuralnetworkformationandsignaltransmissioninHuntington"sDiseaseneuralculture
Neurotoxicitytesting
Preclinicaldrugefficacytesting
Co-culturestudieswithastrocytes
ProductSpecification:
Startingmaterial | Fibroblasts |
Donorgender | Female |
Donorageatsampling | 48yrs |
Donorageofonset | 42yrs |
Reprogrammingmethod | Retroviral |
Inductionmethod | Monolayer&chemicallydefinedmedium |
Size | ≥1.5millioncells |
Kitcomponents | 1vialofNeuralStemCells(≥1.5millioncells)and1bottleofNeuralPlating-XFMedium(30mL) |
Celltype | iPSC-derivedneuralstemcells |
Growthproperties | Adherent |
Shippingconditions | Dryice |
Storageconditions | Liquidnitrogen |